Tags

Type your tag names separated by a space and hit enter

Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial.
Menopause. 2008 Mar-Apr; 15(2):310-8.M

Abstract

OBJECTIVE

To compare the effectiveness and tolerability of gabapentin with placebo for the treatment of hot flashes in women who enter menopause naturally.

DESIGN

A randomized, double-blind, placebo-controlled trial was conducted across the greater Toronto area between March 2004 and April 2006 in the community and primary care settings. Eligible participants were 200 women in natural menopause, aged 45 to 65 years, having at least 14 hot flashes per week. Study participants were randomized to receive gabapentin 300 mg oral capsules or placebo three times daily for 4 weeks. The primary outcome measure was the mean percentage change from baseline to week 4 in daily hot flash score, determined from participant diaries. Secondary outcome measures included changes in weekly mean hot flash scores and frequencies, quality of life, and adverse events.

RESULTS

Of the 197 participants, 193 (98%) completed the study. Analysis was by intention to treat. Hot flash scores decreased by 51% (95% CI: 43%-58%) in the gabapentin group, compared with 26% (95% CI: 18%-35%) on placebo, from baseline to week 4. This twofold improvement was statistically significant (P < 0.001). The Menopause-Specific Quality-of-Life vasomotor score decreased by 1.7 (95% CI: 1.3-2.1; P < 0.001) in the gabapentin group. These women reported greater dizziness (18%), unsteadiness (14%), and drowsiness (12%) at week 1 compared with those taking placebo; however, these symptoms improved by week 2 and returned to baseline levels by week 4.

CONCLUSIONS

Gabapentin at 900 mg/day is an effective and well-tolerated treatment for hot flashes.

Authors+Show Affiliations

The Scarborough Hospital, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. dbutt@tsh.toNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17917611

Citation

Butt, Debra A., et al. "Gabapentin for the Treatment of Menopausal Hot Flashes: a Randomized Controlled Trial." Menopause (New York, N.Y.), vol. 15, no. 2, 2008, pp. 310-8.
Butt DA, Lock M, Lewis JE, et al. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008;15(2):310-8.
Butt, D. A., Lock, M., Lewis, J. E., Ross, S., & Moineddin, R. (2008). Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause (New York, N.Y.), 15(2), 310-8.
Butt DA, et al. Gabapentin for the Treatment of Menopausal Hot Flashes: a Randomized Controlled Trial. Menopause. 2008 Mar-Apr;15(2):310-8. PubMed PMID: 17917611.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. AU - Butt,Debra A, AU - Lock,Michael, AU - Lewis,Jacqueline E, AU - Ross,Sue, AU - Moineddin,Rahim, PY - 2007/10/6/pubmed PY - 2008/7/10/medline PY - 2007/10/6/entrez SP - 310 EP - 8 JF - Menopause (New York, N.Y.) JO - Menopause VL - 15 IS - 2 N2 - OBJECTIVE: To compare the effectiveness and tolerability of gabapentin with placebo for the treatment of hot flashes in women who enter menopause naturally. DESIGN: A randomized, double-blind, placebo-controlled trial was conducted across the greater Toronto area between March 2004 and April 2006 in the community and primary care settings. Eligible participants were 200 women in natural menopause, aged 45 to 65 years, having at least 14 hot flashes per week. Study participants were randomized to receive gabapentin 300 mg oral capsules or placebo three times daily for 4 weeks. The primary outcome measure was the mean percentage change from baseline to week 4 in daily hot flash score, determined from participant diaries. Secondary outcome measures included changes in weekly mean hot flash scores and frequencies, quality of life, and adverse events. RESULTS: Of the 197 participants, 193 (98%) completed the study. Analysis was by intention to treat. Hot flash scores decreased by 51% (95% CI: 43%-58%) in the gabapentin group, compared with 26% (95% CI: 18%-35%) on placebo, from baseline to week 4. This twofold improvement was statistically significant (P < 0.001). The Menopause-Specific Quality-of-Life vasomotor score decreased by 1.7 (95% CI: 1.3-2.1; P < 0.001) in the gabapentin group. These women reported greater dizziness (18%), unsteadiness (14%), and drowsiness (12%) at week 1 compared with those taking placebo; however, these symptoms improved by week 2 and returned to baseline levels by week 4. CONCLUSIONS: Gabapentin at 900 mg/day is an effective and well-tolerated treatment for hot flashes. SN - 1072-3714 UR - https://www.unboundmedicine.com/medline/citation/17917611/Gabapentin_for_the_treatment_of_menopausal_hot_flashes:_a_randomized_controlled_trial_ L2 - https://doi.org/10.1097/gme.0b013e3180dca175 DB - PRIME DP - Unbound Medicine ER -